{"ModuleTitle": "Company Description", "CompanyName": "Verastem, Inc.", "Symbol": "VSTM", "Address": "117 KENDRICK STREET SUITE 500, NEEDHAM, Massachusetts, 02494, United States of America", "Phone": "(781) 292-4200", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company focused on developing and commercializing\r\nmedicines to improve the survival and quality of life of cancer patients. Our\r\nmarketed product, COPIKTRA\u00ae (duvelisib) capsules, and most advanced product\r\ncandidates, defactinib and CH5126766 also referred to as VS-6766, utilize a\r\nmulti-faceted approach designed to treat cancers originating either in the blood\r\nor major organ systems. We are currently developing duvelisib and our product\r\ncandidates in both preclinical and clinical studies as potential therapies for\r\ncertain cancers, including leukemia, lymphoma, lung cancer, mesothelioma,\r\novarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f11%2f0001558370-20-002421.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Brian M. Stuglik", "title": "Chief Executive Officer & Independent Director"}, {"name": "Daniel W. Paterson", "title": "President & Chief Operating Officer"}, {"name": "Jonathan Pachter", "title": "Chief Scientific Officer"}, {"name": "Robert E. Gagnon", "title": "Chief Financial & Business Officer"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}